CXCL13 and neoplasm: Accordingly, prevention of early B-cells recruitment in KrasG12D-PDEC orthotopically implanted mice with anti-CXCL13 treatment also resulted in reduced growth of the orthotopic lesions reinforcing possible tumor promoting properties of B-lymphocytes in the initial stages of PDAC development (66).